Stimulation in the nucleus entopeduncularis affects neuronal activity in the nucleus accumbens and medial prefrontal cortex after apomorphine-induced deficient prepulse inhibition in rats
Objective: The aim of our study was to investigate the effects of stimulation in the rat entopeduncular nucleus (EPN) on single neuronal activity of the…Apomorphine infusion does not impair cognitive action control in Parkinson’s disease
Objective: We sought to verify that apomorphine infusion did not alter cognitive action control.We sought to verify that apomorphine infusion did not alter cognitive action…Double-blind, randomized, placebo-controlled, Phase III study (TOLEDO) to evaluate the efficacy of apomorphine subcutaneous infusion in reducing OFF time in Parkinson’s disease patients with motor fluctuations not well controlled on optimized conventional treatment
Objective: The TOLEDO Study (NCT02006121) is a prospective, randomized, multicenter, double-blind, Phase III trial undertaken to investigate the efficacy of apomorphine subcutaneous infusion (APO) compared…Study Design of an Efficacy and Safety Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of APL-130277 in the Treatment of OFF Episodes (CTH-300)
Objective: To review the unique features of the ongoing Phase 3 trial for APL-130277. Background: Patients with Parkinson’s disease (PD) frequently develop problematic OFF episodes…Efficacy of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson’s disease: results from the Phase 3 study dose-titration phase
Objective: To determine the dose of APL-130277 required by each patient with Parkinson’s Disease (PD) to turn from OFF to Full ON. This dose is…Safety of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson’s disease: Preliminary Results from a Phase III Study
Objective: To determine the safety of single treatments of APL-130277 in patients with Parkinson’s disease (PD). Background: Patients with Parkinson’s disease (PD) frequently develop problematic…Disease severity is not predictive of the dose required for apomorphine sublingual film (APL-130277) to convert a patient with Parkinson’s disease(PD) from OFF to fully ON: Preliminary Results from a Phase III Study
Objective: To determine if baseline disease severity could be correlated to the effective dose of APL-130277 that was required to turn a patient with PD…ND0701: A new concentrated formulation of Apomorphine for continuous subcutaneous administration – human PK data
Objective: To evaluate the PK and relative bioavailability of ND0701, a subcutaneously (SC) infused apomorphine-base product candidate, and a commercial apomorphine-HCl product. The secondary objective…Pharmaeconomic study of the treatment of advanced Parkinson’s disease.
Objective: Conduct a comparative pharmacoeconomic analysis of the use of subcutaneous apomorphine infusion pump (SAIP), continuous levodopa/carbidopa duodenal infusión (LDI) and deep brain stimulation (DBS). Background:…Oral apomorphine film (APL-130277) produces no buccal mucosal irritation: Results of a toxicological study
Objective: Determine the tolerance of and potential for cheek pouch buccal mucosa irritation following the administration of apomorphine film (APL-130277). Background: APL-130277 is a sublingual…
- « Previous Page
- 1
- …
- 9
- 10
- 11
- 12
- 13
- Next Page »